Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Molecular Diagnostic Techniques | 4 | 2020 | 72 | 1.230 |
Why?
|
| Microbiological Techniques | 5 | 2019 | 24 | 0.960 |
Why?
|
| Legionellosis | 1 | 2024 | 6 | 0.910 |
Why?
|
| Legionella | 1 | 2024 | 16 | 0.900 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 39 | 0.890 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 77 | 0.850 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 329 | 0.850 |
Why?
|
| Bacteria | 4 | 2017 | 500 | 0.850 |
Why?
|
| Bacteremia | 2 | 2014 | 105 | 0.830 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 301 | 0.820 |
Why?
|
| Betacoronavirus | 3 | 2020 | 270 | 0.800 |
Why?
|
| Mycoplasma genitalium | 1 | 2022 | 3 | 0.770 |
Why?
|
| Mycoplasma Infections | 1 | 2022 | 9 | 0.770 |
Why?
|
| Gonorrhea | 1 | 2022 | 23 | 0.760 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 32 | 0.750 |
Why?
|
| Mycobacterium chelonae | 1 | 2021 | 4 | 0.720 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 28 | 0.700 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 102 | 0.670 |
Why?
|
| Immunoglobulin G | 3 | 2021 | 460 | 0.650 |
Why?
|
| Immunoglobulin A | 1 | 2020 | 87 | 0.650 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 374 | 0.620 |
Why?
|
| Bacteriological Techniques | 2 | 2019 | 40 | 0.600 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 202 | 0.590 |
Why?
|
| Blood | 2 | 2017 | 68 | 0.590 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 230 | 0.590 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 315 | 0.580 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2014 | 79 | 0.570 |
Why?
|
| Influenza, Human | 2 | 2018 | 343 | 0.560 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2017 | 26 | 0.550 |
Why?
|
| Sensitivity and Specificity | 9 | 2024 | 2009 | 0.490 |
Why?
|
| Actinomyces | 1 | 2015 | 5 | 0.480 |
Why?
|
| Earache | 1 | 2015 | 4 | 0.480 |
Why?
|
| Actinomycosis | 1 | 2015 | 12 | 0.470 |
Why?
|
| Maxillary Sinusitis | 1 | 2015 | 14 | 0.470 |
Why?
|
| Neisseria meningitidis, Serogroup Y | 1 | 2014 | 2 | 0.460 |
Why?
|
| Arthritis, Infectious | 1 | 2014 | 17 | 0.460 |
Why?
|
| Specimen Handling | 1 | 2014 | 103 | 0.430 |
Why?
|
| Knee Joint | 1 | 2014 | 162 | 0.420 |
Why?
|
| Adenoviridae Infections | 1 | 2012 | 16 | 0.390 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 45 | 0.360 |
Why?
|
| Serologic Tests | 2 | 2020 | 43 | 0.330 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 145 | 0.320 |
Why?
|
| Fatal Outcome | 2 | 2024 | 299 | 0.310 |
Why?
|
| Nasopharynx | 2 | 2020 | 50 | 0.300 |
Why?
|
| Humans | 31 | 2024 | 92352 | 0.300 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 111 | 0.250 |
Why?
|
| Toxoplasmosis, Congenital | 1 | 2024 | 49 | 0.220 |
Why?
|
| Blood Gas Analysis | 2 | 2020 | 37 | 0.210 |
Why?
|
| Automation, Laboratory | 2 | 2020 | 12 | 0.210 |
Why?
|
| Microscopy | 2 | 2014 | 88 | 0.210 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2020 | 40 | 0.200 |
Why?
|
| Chlamydia trachomatis | 1 | 2022 | 15 | 0.190 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2022 | 17 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2022 | 4474 | 0.180 |
Why?
|
| Helicobacter Infections | 1 | 2021 | 37 | 0.170 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 38 | 0.170 |
Why?
|
| Gastritis | 1 | 2021 | 36 | 0.170 |
Why?
|
| Syringes | 1 | 2020 | 14 | 0.170 |
Why?
|
| Plasma Cells | 1 | 2021 | 86 | 0.170 |
Why?
|
| Stomach | 1 | 2021 | 111 | 0.170 |
Why?
|
| Biopsy | 2 | 2021 | 1194 | 0.170 |
Why?
|
| Child, Preschool | 3 | 2021 | 3806 | 0.170 |
Why?
|
| Blood Specimen Collection | 1 | 2020 | 28 | 0.170 |
Why?
|
| Time Factors | 5 | 2017 | 5431 | 0.170 |
Why?
|
| Adult | 7 | 2021 | 27547 | 0.170 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 158 | 0.160 |
Why?
|
| Lung Transplantation | 1 | 2024 | 350 | 0.160 |
Why?
|
| Pathology, Surgical | 1 | 2019 | 11 | 0.160 |
Why?
|
| Cross Reactions | 4 | 2021 | 110 | 0.160 |
Why?
|
| Nasal Mucosa | 1 | 2020 | 191 | 0.160 |
Why?
|
| Chicago | 3 | 2020 | 1463 | 0.160 |
Why?
|
| Male | 11 | 2022 | 43929 | 0.160 |
Why?
|
| Pharyngitis | 1 | 2019 | 15 | 0.160 |
Why?
|
| Catheters | 1 | 2020 | 86 | 0.160 |
Why?
|
| Streptococcus pyogenes | 1 | 2019 | 35 | 0.160 |
Why?
|
| Autopsy | 1 | 2019 | 123 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 150 | 0.160 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 55 | 0.150 |
Why?
|
| Bordetella Infections | 1 | 2018 | 5 | 0.150 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 318 | 0.150 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2018 | 15 | 0.150 |
Why?
|
| Clostridium Infections | 1 | 2020 | 125 | 0.150 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 24 | 0.140 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2018 | 83 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2018 | 66 | 0.140 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2017 | 8 | 0.140 |
Why?
|
| Influenza B virus | 1 | 2017 | 32 | 0.140 |
Why?
|
| Lymphotoxin alpha1, beta2 Heterotrimer | 1 | 2017 | 4 | 0.140 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2017 | 28 | 0.140 |
Why?
|
| Pandemics | 2 | 2020 | 807 | 0.140 |
Why?
|
| Fungi | 1 | 2017 | 67 | 0.140 |
Why?
|
| Workflow | 1 | 2017 | 80 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 152 | 0.130 |
Why?
|
| False Positive Reactions | 3 | 2024 | 220 | 0.130 |
Why?
|
| Influenza A virus | 1 | 2017 | 172 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 108 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 289 | 0.130 |
Why?
|
| Seminal Vesicles | 1 | 2016 | 39 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2020 | 429 | 0.130 |
Why?
|
| Maxillary Sinus | 1 | 2015 | 22 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2016 | 153 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 476 | 0.120 |
Why?
|
| Oseltamivir | 1 | 2015 | 20 | 0.110 |
Why?
|
| Oxygen | 1 | 2020 | 762 | 0.110 |
Why?
|
| Histocytochemistry | 2 | 2012 | 131 | 0.110 |
Why?
|
| Middle Aged | 7 | 2021 | 27045 | 0.110 |
Why?
|
| Viruses | 1 | 2015 | 75 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2015 | 99 | 0.110 |
Why?
|
| Yeasts | 1 | 2013 | 49 | 0.110 |
Why?
|
| Sepsis | 1 | 2017 | 353 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2017 | 441 | 0.100 |
Why?
|
| Mycoses | 1 | 2013 | 46 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6918 | 0.100 |
Why?
|
| Temperature | 1 | 2014 | 405 | 0.100 |
Why?
|
| Female | 9 | 2024 | 47901 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 808 | 0.100 |
Why?
|
| Child | 4 | 2021 | 7309 | 0.100 |
Why?
|
| Immunoglobulin M | 2 | 2024 | 161 | 0.100 |
Why?
|
| Family Health | 1 | 2012 | 158 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2013 | 185 | 0.090 |
Why?
|
| Microbiota | 1 | 2017 | 412 | 0.090 |
Why?
|
| DNA, Bacterial | 3 | 2019 | 247 | 0.090 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2011 | 4 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2015 | 498 | 0.090 |
Why?
|
| Pseudomonas | 1 | 2011 | 52 | 0.090 |
Why?
|
| Infant | 1 | 2017 | 3206 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 924 | 0.080 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 101 | 0.080 |
Why?
|
| Aged | 5 | 2021 | 19953 | 0.080 |
Why?
|
| Antigens, Viral | 2 | 2021 | 133 | 0.080 |
Why?
|
| Tinea Capitis | 1 | 2009 | 2 | 0.080 |
Why?
|
| Young Adult | 2 | 2021 | 6629 | 0.080 |
Why?
|
| Adolescent | 2 | 2021 | 9495 | 0.070 |
Why?
|
| Lung | 2 | 2012 | 1337 | 0.070 |
Why?
|
| Microsporum | 1 | 2007 | 1 | 0.070 |
Why?
|
| Tinea Favosa | 1 | 2007 | 1 | 0.070 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2019 | 38 | 0.070 |
Why?
|
| Multiplex Polymerase Chain Reaction | 2 | 2018 | 36 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 1761 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 1804 | 0.060 |
Why?
|
| Antibodies, Protozoan | 1 | 2024 | 42 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2793 | 0.050 |
Why?
|
| Prenatal Diagnosis | 1 | 2024 | 110 | 0.050 |
Why?
|
| Toxoplasma | 1 | 2024 | 116 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2021 | 24 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2021 | 71 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 68 | 0.040 |
Why?
|
| Epitopes | 1 | 2021 | 249 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 127 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 265 | 0.040 |
Why?
|
| Frozen Sections | 1 | 2019 | 49 | 0.040 |
Why?
|
| Pharynx | 1 | 2019 | 44 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 21 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 501 | 0.040 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 6 | 0.040 |
Why?
|
| Bordetella pertussis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 136 | 0.040 |
Why?
|
| Eggs | 1 | 2018 | 13 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 13 | 0.040 |
Why?
|
| Ferrets | 1 | 2018 | 48 | 0.040 |
Why?
|
| Medical Audit | 1 | 2018 | 39 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2018 | 76 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 2506 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 399 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 119 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 105 | 0.030 |
Why?
|
| Inpatients | 1 | 2020 | 332 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2017 | 197 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 91 | 0.030 |
Why?
|
| Seasons | 1 | 2018 | 241 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 357 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 3113 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 753 | 0.030 |
Why?
|
| United States | 2 | 2019 | 7367 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 324 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2021 | 9694 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 499 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1847 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 130 | 0.030 |
Why?
|
| Phylogeny | 1 | 2018 | 1231 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 2098 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2979 | 0.020 |
Why?
|
| Inflammation | 1 | 2017 | 1024 | 0.020 |
Why?
|
| Mycobacterium avium Complex | 1 | 2011 | 6 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 28 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2011 | 52 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2011 | 259 | 0.020 |
Why?
|
| Griseofulvin | 1 | 2009 | 1 | 0.020 |
Why?
|
| Trichophyton | 1 | 2009 | 1 | 0.020 |
Why?
|
| Africa, Western | 1 | 2009 | 11 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 1191 | 0.020 |
Why?
|
| Ketoconazole | 1 | 2009 | 24 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2009 | 125 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 28059 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 876 | 0.020 |
Why?
|
| HIV Infections | 1 | 2016 | 896 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4213 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3023 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 1768 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 907 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 12133 | 0.010 |
Why?
|